fibronostics physician tips nash

Physician Tips: It’s time to talk about NASH!

Depending on the study, incidence of non-alcoholic fatty liver disease affects from 33% to 40% of your patients with 3% to 12% having progressed to non-alcoholic steatohepatitis or NASH. While deaths from other common conditions are declining, those due to liver disease have been increasing dramatically.[i]

It is a silent disease with no symptoms until it has reached a state of injury with hepatocellular ballooning or inflammation. NASH is closely related to the growing epidemic of obesity, pre-diabetes, and diabetes, and can be seen as the liver manifestation of metabolic syndrome. For those reasons, a growing number of specialists around the world are saying it is time to talk about NASH with your at-risk patients.

"Fatty liver disease and NASH are impending public health epidemics that have gone virtually unrecognized and untreated, leading to unnecessary patient and family suffering and death,” says Donna Cryer, Global Liver Institute CEO, in a press release.

A liver transplant recipient herself, she explains, “We are grateful that International NASH Day was started, and feel confident that under the leadership of the global liver advocacy community this initiative will continue to grow into a high-profile, high-impact movement sustained by the public, policymakers, clinicians, researchers, and patients around the world."

Early diagnosis is key to reversing the trend in NASH, which is now possible with newer non-invasive diagnostic tests that can reduce the need for invasive biopsy at lower cost and lower risk. In addition, such tests may produce result reports designed for quick interpretation that are also easy to share as an educational tool to help patients understand their liver disease risk and talk about NASH.

To continue raising awareness among physicians and patients, the NASH Education Program is kicking off the 2nd annual International NASH Day on June 12, 2019 with global day of action that includes a total of 21 conferences, 50 events including screenings, policy briefings, education events online and scheduled events in 25 cities around the world. The goal is to motivate physicians and patients to talk about the risks of liver disease.

To help you raise awareness in your practice, the Global Liver Institute is encouraging primary care and liver specialists to participate in the NASH DAY Education Program. The two organizations have produced an array of infographics and videos you can use to help raise awareness, educate and inform your patients who are at risk of liver disease.

Fibronostics is committed to leveraging the benefits of technology to improve lives, and deliver high-quality, life-improving disease educationevaluation and monitoring. Our LiverFASt™ screen is a low-cost, evidence-based test for liver fibrosis and early detection of steatosis, and NASH. The LiverFASt™ report is designed for quick interpretation and is an easy to share educational tool to help patients understand their liver disease risk.

HealthFACTR is an algorithm-based, broad spectrum health assessment tool targeting & visualizing several of the most critical risks to a person’s health and longevity. It is a scientifically based test addressing key focus areas adversely affecting human health. It has robust clinical support using state-of-the-art gold standard testing methods and backed up by hundreds of clinical support papers. Heart disease, Diabetes, Stroke, Liver disease, Obstructive Sleep Apnea, Cholesterol, Triglyceride, Blood Pressure, HDL, LDL, Diet Assessment, Fitness Assessment, Fitness Goals, Body Fat Analysis - are measured, individual risk assessed, and actions recommended to reduce disease progression. HealthFACTR provides detailed visualization into a person’s metabolic health risks and fitness.


Contact us via email, or by phone at 1-888-552-1603 today to learn more about our LiverFASt™ family of diagnostic tests and HealthFACTR services. 


[i] Williams R , et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 2014;384:1953–97.doi:10.1016/S0140-6736(14)61838-9

<iframe width="560" height="315" src="" frameborder="0" allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>

Fibronostics Offices

Strategic locations for global coverage.

About Fibronostics

We are a team of life science experts, physicians, mathematicians, health IT professionals and software architects.

Orlando Offices

Singapore Offices